SK+F
Bangladeshi pharmaceutical company
From Wikipedia, the free encyclopedia
Eskayef Pharmaceuticals Ltd., also known as SK+F, is a pharmaceutical company in Bangladesh. It belongs to the Transcom Group.[1] Simeen Rahman is the managing director and CEO of the company.[1][2]
| |
| Company type | Private Limited |
|---|---|
| Industry | Pharmaceutical Industry |
| Founded | 1990 |
| Founder | Latifur Rahman |
| Headquarters | Plot: 82, Road: 14 Block - B, Banani, , Bangladesh |
Key people | Simeen Rahman (Managing Director & CEO) |
| Revenue |  US$300 million |
| Parent | Transcom Group |
| Website | skfbd |
History
Eskayef Bangladesh Ltd., a successor of Smith, Kline & French in Bangladesh, was acquired by Transcom in 1990.[1] According to an IMS report, the company was among the top six pharmaceutical companies operating in Bangladesh in terms of sales in 2021.[3] By 2021, it exported finished products to 65 countries.[1] The company was renamed Eskayef Pharmaceuticals Limited in January 2017.[4]
Products
The company is engaged in the manufacture and marketing of a wide range of therapeutic drugs, bulk pellets and animal health and nutrition products[5] including the oral anti covid medication molnupiravir[6] & nirmatrelvir co-packaged with ritonavir and injectable remdesivir.
